Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2021-02, Vol.184 (2), p.345-347 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 347 |
|---|---|
| container_issue | 2 |
| container_start_page | 345 |
| container_title | British journal of dermatology (1951) |
| container_volume | 184 |
| creator | Toussaint, F. Erdmann, M. Grosch, E. Schliep, S. Schuler, G. Dummer, R. Heinzerling, L. |
| description | |
| doi_str_mv | 10.1111/bjd.19470 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2431825201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2486447012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3880-f4b1202ffbcf082d3451daf46e6268227df8e0cca318ecd56902064f3fbbb67b3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS1ERacDC14AWWIDi7T-SZzMEqZQqCqxGdaR7ditR4kdbKft7HgEXqIvxpP0TjOwQMJe-Ernu8fXPgi9puSUwjpT2-6UrsqaPEMLykVVMMr5c7QghNQFWQl-jE5S2hJCOanIC3TMWS1gVwv0sInSJ2d8xtGkMfhkcA7Yu9vQT4NUWPoOlF6OIEibTcTO297du73oPJZ4lPmp_87lGzxGEOIO6ylLb8KU8Pq8-f3z1xiSy-4WPK6v4aK0L83oOhOHkGMYncZ6l0MO91BtoEGbvsf9bhhvwiBfoiMr-2ReHc4l-v7502b9pbj6dvF1_eGq0LxpSGFLRRlh1iptScM6Xla0k7YURjDRMFZ3tjFEa8lpY3RXiRVhRJSWW6WUqBVfonez7xjDj8mk3A4u7SeZ39KyEjpZxeAjl-jtP-g2TNHDdEA1ooQ0KAPq_UzpGFKKxraHD2opaffZtZBd-5QdsG8OjpMaTPeX_BMWAGczcOd6s_u_U_vx8ny2fASvU6jg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486447012</pqid></control><display><type>article</type><title>Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Toussaint, F. ; Erdmann, M. ; Grosch, E. ; Schliep, S. ; Schuler, G. ; Dummer, R. ; Heinzerling, L.</creator><creatorcontrib>Toussaint, F. ; Erdmann, M. ; Grosch, E. ; Schliep, S. ; Schuler, G. ; Dummer, R. ; Heinzerling, L.</creatorcontrib><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/bjd.19470</identifier><identifier>PMID: 32767675</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>CD8 antigen ; CD8-Positive T-Lymphocytes ; Cytotoxicity ; Humans ; Immunotherapy ; Infliximab ; Lymphoma ; Lymphoma, T-Cell, Cutaneous - drug therapy ; Monoclonal antibodies ; Neoplasm Recurrence, Local - drug therapy ; Nivolumab - therapeutic use ; Skin Neoplasms - drug therapy ; T-cell lymphoma ; Targeted cancer therapy ; TNF inhibitors ; Tumor necrosis factor-α</subject><ispartof>British journal of dermatology (1951), 2021-02, Vol.184 (2), p.345-347</ispartof><rights>2020 The Authors. published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3880-f4b1202ffbcf082d3451daf46e6268227df8e0cca318ecd56902064f3fbbb67b3</citedby><cites>FETCH-LOGICAL-c3880-f4b1202ffbcf082d3451daf46e6268227df8e0cca318ecd56902064f3fbbb67b3</cites><orcidid>0000-0002-9565-3180 ; 0000-0002-2279-6906</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjd.19470$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjd.19470$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32767675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toussaint, F.</creatorcontrib><creatorcontrib>Erdmann, M.</creatorcontrib><creatorcontrib>Grosch, E.</creatorcontrib><creatorcontrib>Schliep, S.</creatorcontrib><creatorcontrib>Schuler, G.</creatorcontrib><creatorcontrib>Dummer, R.</creatorcontrib><creatorcontrib>Heinzerling, L.</creatorcontrib><title>Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes</subject><subject>Cytotoxicity</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Infliximab</subject><subject>Lymphoma</subject><subject>Lymphoma, T-Cell, Cutaneous - drug therapy</subject><subject>Monoclonal antibodies</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Nivolumab - therapeutic use</subject><subject>Skin Neoplasms - drug therapy</subject><subject>T-cell lymphoma</subject><subject>Targeted cancer therapy</subject><subject>TNF inhibitors</subject><subject>Tumor necrosis factor-α</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS1ERacDC14AWWIDi7T-SZzMEqZQqCqxGdaR7ditR4kdbKft7HgEXqIvxpP0TjOwQMJe-Ernu8fXPgi9puSUwjpT2-6UrsqaPEMLykVVMMr5c7QghNQFWQl-jE5S2hJCOanIC3TMWS1gVwv0sInSJ2d8xtGkMfhkcA7Yu9vQT4NUWPoOlF6OIEibTcTO297du73oPJZ4lPmp_87lGzxGEOIO6ylLb8KU8Pq8-f3z1xiSy-4WPK6v4aK0L83oOhOHkGMYncZ6l0MO91BtoEGbvsf9bhhvwiBfoiMr-2ReHc4l-v7502b9pbj6dvF1_eGq0LxpSGFLRRlh1iptScM6Xla0k7YURjDRMFZ3tjFEa8lpY3RXiRVhRJSWW6WUqBVfonez7xjDj8mk3A4u7SeZ39KyEjpZxeAjl-jtP-g2TNHDdEA1ooQ0KAPq_UzpGFKKxraHD2opaffZtZBd-5QdsG8OjpMaTPeX_BMWAGczcOd6s_u_U_vx8ny2fASvU6jg</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Toussaint, F.</creator><creator>Erdmann, M.</creator><creator>Grosch, E.</creator><creator>Schliep, S.</creator><creator>Schuler, G.</creator><creator>Dummer, R.</creator><creator>Heinzerling, L.</creator><general>Oxford University Press</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9565-3180</orcidid><orcidid>https://orcid.org/0000-0002-2279-6906</orcidid></search><sort><creationdate>202102</creationdate><title>Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma</title><author>Toussaint, F. ; Erdmann, M. ; Grosch, E. ; Schliep, S. ; Schuler, G. ; Dummer, R. ; Heinzerling, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3880-f4b1202ffbcf082d3451daf46e6268227df8e0cca318ecd56902064f3fbbb67b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes</topic><topic>Cytotoxicity</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Infliximab</topic><topic>Lymphoma</topic><topic>Lymphoma, T-Cell, Cutaneous - drug therapy</topic><topic>Monoclonal antibodies</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Nivolumab - therapeutic use</topic><topic>Skin Neoplasms - drug therapy</topic><topic>T-cell lymphoma</topic><topic>Targeted cancer therapy</topic><topic>TNF inhibitors</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toussaint, F.</creatorcontrib><creatorcontrib>Erdmann, M.</creatorcontrib><creatorcontrib>Grosch, E.</creatorcontrib><creatorcontrib>Schliep, S.</creatorcontrib><creatorcontrib>Schuler, G.</creatorcontrib><creatorcontrib>Dummer, R.</creatorcontrib><creatorcontrib>Heinzerling, L.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toussaint, F.</au><au>Erdmann, M.</au><au>Grosch, E.</au><au>Schliep, S.</au><au>Schuler, G.</au><au>Dummer, R.</au><au>Heinzerling, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2021-02</date><risdate>2021</risdate><volume>184</volume><issue>2</issue><spage>345</spage><epage>347</epage><pages>345-347</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><cop>England</cop><pub>Oxford University Press</pub><pmid>32767675</pmid><doi>10.1111/bjd.19470</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-9565-3180</orcidid><orcidid>https://orcid.org/0000-0002-2279-6906</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2021-02, Vol.184 (2), p.345-347 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2431825201 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Oxford University Press Journals All Titles (1996-Current) |
| subjects | CD8 antigen CD8-Positive T-Lymphocytes Cytotoxicity Humans Immunotherapy Infliximab Lymphoma Lymphoma, T-Cell, Cutaneous - drug therapy Monoclonal antibodies Neoplasm Recurrence, Local - drug therapy Nivolumab - therapeutic use Skin Neoplasms - drug therapy T-cell lymphoma Targeted cancer therapy TNF inhibitors Tumor necrosis factor-α |
| title | Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T08%3A36%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transient%20response%20to%20nivolumab%20and%20relapse%20after%20infliximab%20in%20a%20patient%20with%20primary%20cutaneous%20CD8%E2%80%90positive%20aggressive%20epidermotropic%20cytotoxic%20T%E2%80%90cell%20lymphoma&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Toussaint,%20F.&rft.date=2021-02&rft.volume=184&rft.issue=2&rft.spage=345&rft.epage=347&rft.pages=345-347&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1111/bjd.19470&rft_dat=%3Cproquest_cross%3E2486447012%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2486447012&rft_id=info:pmid/32767675&rfr_iscdi=true |